{"altmetric_id":3085571,"counts":{"readers":{"mendeley":9,"citeulike":0,"connotea":0},"total":{"posts_count":2},"twitter":{"unique_users_count":2,"unique_users":["fsgimt","TumorImm_papers"],"posts_count":2}},"selected_quotes":["Good morning! Access a free editorial from the latest issue of #immunotherapy here"],"citation":{"altmetric_jid":"4f6fa61b3cf058f61000772f","authors":["Hafez N","Petrylak DP"],"doi":"10.2217\/imt.14.110","first_seen_on":"2015-01-21T09:44:58+00:00","funders":["niehs"],"issns":[],"issue":"1","journal":"Immunotherapy","last_mentioned_on":1442562722,"links":["http:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/imt.14.110","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25572474?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter"],"pmid":"25572474","pubdate":"2015-01-14T00:00:00+00:00","subjects":["allergyandimmunology"],"title":"Could PD-L1 prove to be an effective therapeutic target for bladder cancer?","type":"article","volume":"7","mendeley_url":"http:\/\/www.mendeley.com\/research\/pdl1-prove-effective-therapeutic-target-bladder-cancer"},"altmetric_score":{"score":0.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.75},"context_for_score":{"all":{"total_number_of_other_articles":6364199,"mean":5.83819851048,"rank":4467831,"this_scored_higher_than_pct":26,"this_scored_higher_than":1661956,"rank_type":"exact","sample_size":6364199,"percentile":26},"similar_age_3m":{"total_number_of_other_articles":193612,"mean":8.5498783230293,"rank":123135,"this_scored_higher_than_pct":31,"this_scored_higher_than":61595,"rank_type":"exact","sample_size":193612,"percentile":31},"this_journal":{"total_number_of_other_articles":364,"mean":2.8032727272727,"rank":231,"this_scored_higher_than_pct":28,"this_scored_higher_than":103,"rank_type":"exact","sample_size":364,"percentile":28},"similar_age_this_journal_3m":{"total_number_of_other_articles":19,"mean":3.9027777777778,"rank":16,"this_scored_higher_than_pct":5,"this_scored_higher_than":1,"rank_type":"exact","sample_size":19,"percentile":5}}},"demographics":{"poster_types":{"member_of_the_public":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":1,"Members of the public":1}},"mendeley":{"by_status":{"Researcher":3,"Student  > Ph. D. Student":1,"Student  > Postgraduate":1,"Other":1,"Student  > Master":1,"Student  > Bachelor":2},"by_discipline":{"Medicine and Dentistry":7,"Agricultural and Biological Sciences":2}}},"geo":{"mendeley":{"KR":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/fsgimt\/status\/557836103454306304","license":"datasift","citation_ids":[3085571],"posted_on":"2015-01-21T09:44:25+00:00","author":{"name":"Immunotherapy Jnl","url":"http:\/\/www.futuremedicine.com\/loi\/imt","image":"https:\/\/pbs.twimg.com\/profile_images\/491494934214483968\/HnYDfiMW_normal.jpeg","description":"Immunotherapy | MEDLINE-indexed journal on the therapeutics that harness the immune system to combat disease | IF 2.716 | Published by Future Science Group","id_on_source":"fsgimt","tweeter_id":"2668753783","geo":{"lt":null,"ln":null},"followers":1216},"tweet_id":"557836103454306304"},{"url":"http:\/\/twitter.com\/TumorImm_papers\/statuses\/644780908894031872","license":"gnip","citation_ids":[3085571],"posted_on":"2015-09-18T07:52:02+00:00","author":{"name":"TumorImmunoPapers","image":"https:\/\/pbs.twimg.com\/profile_images\/741322452093931520\/rQvFtFTA_normal.jpg","description":"A TwitterBot for Cancer Immunology and Tolerance papers on #PubMed. Curated by @adamsnookphd","id_on_source":"TumorImm_papers","tweeter_id":"2829712275","geo":{"lt":null,"ln":null},"followers":665},"tweet_id":"644780908894031872"}]}}